HOPO Therapeutics
HOPO Therapeutics is a clinical-stage pharmaceutical company developing best-in-class treatments for heavy metal poisoning. Designed to be both safer and more effective than existing chelation therapies, the orally-available drug candidates are aimed at treating exposure to a wide range of heavy metals. Priority use cases include radioactive threat isotopes from a nuclear disaster or dirty bomb, for which there is currently no practical treatment; heavy metals in medicines, including gadolinium-based MRI contrast agents and radionuclide therapies; and exposure to environmental contaminants like lead, cadmium, and mercury.